Stock performance snapshot

Bristol-Myers Squibb (BMY) has drawn fresh attention after a solid year-to-date total return of about 9.5%, alongside a 1-year total return near 30.8% and a current share price around US$58.54.

Recent moves show mixed momentum, with the 7-day share price return of 3.8% sitting against a 30-day share price decline of 1.0%. However, the 1-year total shareholder return of 30.8% points to a stronger longer term picture.

If you are comparing Bristol-Myers Squibb with other opportunities in healthcare, it can be useful to see how it stacks up against companies using AI in medicine through 30 healthcare AI stocks

With Bristol-Myers Squibb trading near US$58.54 and flagged as having a possible intrinsic discount of about 51%, the key question is whether the stock is genuinely undervalued or if the market is already pricing in future growth.

Most Popular Narrative: 9.9% Undervalued

According to Evangelos, the current share price around $58.54 sits below a narrative fair value of $65.00, with that gap framed through both earnings guidance and cash flow assumptions.

Full-Year 2024 Highlights:

• Total Revenues: $48.3 billion, a 7% increase from 2023.

• GAAP Loss Per Share: $(4.41), compared to earnings of $3.86 in 2023.

• Non-GAAP EPS: $1.15, a significant decrease from $7.51 in 2023.

• Growth Portfolio Revenues: $22.6 billion, a 17% increase, indicating robust performance of newer products.

Curious how a weaker GAAP and non GAAP earnings picture can still sit beside a higher fair value? The narrative leans heavily on growth portfolio strength, future earnings power, and a cash flow profile that is smoothed across cycles. The key question is how those revenue and margin paths have been modeled to reach $65.00.

Result: Fair Value of $65.00 (UNDERVALUED)

However, you still need to weigh risks such as revenue falling 6.6% year on year and the annual net income decline, which could challenge those fair value assumptions.

Another view on valuation

The earlier narrative fair value of $65.00 leans on earnings power and cash flows, but the market is also weighing simple P/E math. Bristol-Myers Squibb trades on 16.4x earnings, compared with 14.8x for the US pharmaceuticals industry, 22.2x for peers, and a fair ratio of 19.5x that the market could move toward.

If earnings slip from here, paying slightly above the industry but below both peers and the fair ratio could either cap upside or set up a valuation catch up later. The key question is which way the business fundamentals break next.

Next Steps

With mixed signals across returns and valuation, how does all this stack up for you right now, and what feels most important for your thesis? Take a closer look at the balance of potential upside and downside by checking the 3 key rewards and 3 important warning signs.

Looking for more investment ideas?

If you stop here, you might miss stocks that better match your goals, so keep building your watchlist using focused screeners that surface clear, data backed ideas.

• Target potential value opportunities by scanning 51 high quality undervalued stocks that combine pricing pressure with quality fundamentals.
• Strengthen your focus on financial resilience using the solid balance sheet and fundamentals stocks screener (46 results) to spot companies with sturdier capital structures.
• Get ahead of the crowd by reviewing the screener containing 21 high quality undiscovered gems before they appear on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.